Reply to "CRISPR screens are feasible in TP53 wild-type cells" by Haapaniemi, Emma et al.
Correspondence
Reply to “CRISPR screens are feasible in
TP53 wild-type cells”
Emma Haapaniemi1, Sandeep Botla1 , Jenna Persson1,2, Bernhard Schmierer1,2 &
Jussi Taipale1,3,4
Reply to: KR Brown et al (August 2019)
O ur paper “CRISPR/Cas9 genome edit-ing induces a p53-mediated DNAdamage response” (Haapaniemi et
al, 2018) in Nature Medicine demonstrated
that the efficiency of precision gene editing
by homologous recombination is impaired
in the presence of functional p53. We
provided evidence that Cas9 nuclease activ-
ity causes a p53-dependent, transient G1-
phase arrest, which we hypothesized to
cause the observed p53-dependent decrease
in precise, template-mediated gene editing.
Based on these results, we advised caution
in therapeutic gene editing, where selecting
cells that edit well could lead to inadver-
tent co-selection of cells with a suboptimal
DNA damage checkpoint. Selection (or use)
of such cells should be avoided in a clini-
cal setting, as they may be at an increased
risk for malignant transformation. In a co-
submitted manuscript, Ihry et al (2018)
reported similar findings in another cell
line. These results have since been indepen-
dently reproduced by several groups using
RPE-1 cells and other normal human cell
types (Li et al, 2018; Cullot et al, 2019;
preprint: Geisinger & Stearns, 2019; Schiroli
et al, 2019; preprint: van den Berg et al,
2019). The significant attention that our
work received was due to the relevance of
our conclusions for genome editing in
normal human cells and for the develop-
ment of cell-based therapies. Many investi-
gators have since taken a constructive
approach to the challenge posed by p53
activation in their respective systems and
have taken major steps in designing
reagents and protocols that decrease the
p53 response in clinically relevant cells
(Schiroli et al, 2019).
The correspondence by Brown et al
creates the impression that the main topic of
our paper was CRISPR loss-of-function
screening and that we had argued that such
screening is not feasible in p53 wild-type
cells. This is incorrect. We had originally
discovered the p53 effect when comparing
the CRISPR knock-out screening perfor-
mance of several Cas9 expressing tumor cell
lines and the normal, hTERT immortalized
human cell line RPE-1. To demonstrate the
motivation for our study, we included our
initial genetic screening experiment in RPE-1
cells. This screen identified the p53/p21/
pRB pathway, but did not show the clear
“drop-out” of guides against essential genes
that we had observed in a set of tumor cell
lines. Follow-up experiments indicated that
the drop-out performance of a p53 null RPE-
1 line was superior to that of the wild-type,
which provided a first clue that Cas9 might
induce a p53-mediated DNA damage
response. We then continued to analyze the
effect of p53 down-regulation on precision
genome editing, which was the actual topic
of our paper.
Due to our main focus, the medium of
publication, and the very brief format, we
did not extensively discuss the implications
of our work on applications of Cas9 in basic
research in general and in CRISPR “drop-
out” screening in particular, only adding
two short sentences within the main text:
“DSBs introduced by CRISPR–Cas9 trigger a
transient, p53-dependent cell cycle arrest
mediated through p21 and pRB, irrespective
of the locus targeted. This generic penalty of
DNA cutting masks guide-specific effects,
hampering guide dropout screens that are
aimed at identifying genes whose loss leads
to cell death or decreased cell proliferation.”
In their correspondence, Brown et al first
misinterpret and then object to this state-
ment, and put forward two main lines of
argument: (i) CRISPR drop-out screens are
feasible in p53WT cells and the induction of
a p53 response is “not a major concern”,
and (ii) screening should always be
performed in a specific way that includes
pre-selection of cell lines or clones that
perform exceptionally well in screening.
Our statement about drop-out screening
being “hampered”, i.e., being made more
difficult, referred to p53WT RPE-1 hTERT
cells only, and not to tumor cells, many of
which display no p53-mediated DNA
damage response, or a weaker response than
that observed in RPE1 cells (preprint:
Geisinger & Stearns, 2019). We agree with
Brown et al that drop-out screening using
Cas9 nuclease can be feasible in p53WT cells
under conditions that are different from
those used in our work; this is in fact what
our original transient arrest model (above in
italic typeface) predicts, and we have never
claimed otherwise.
What our data do show is increased noise
caused by the DNA damage checkpoint in
RPE-1 p53WT cells. This result was obtained
in a direct side-by-side comparison of
screening performance of RPE-1 WT and
RPE-1 p53/ cells using the same virus
library—an experiment which Brown et al
notably have not performed. Although defi-
nite conclusions cannot be made based on
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the evidence they provide due to this lack of
paired data with the same library, the perfor-
mance of the Brown et al p53 null and WT
screens is in fact consistent with the p53
response also hampering their screens: In a
MAGeCK analysis (Li et al, 2014) of Brown
et al’s raw data, the p53 null screen recovers
approx. three times as many hits as the p53
WT screen at an FDR < 0.05 (533 vs. 170,
average of two replicates), despite the fact
that the p53 null screen was performed
using inferior experimental design and a less
advanced library (see below). We believe
that the difference between our analysis
with standard statistical tools and Brown
et al’s complex machine-learning measure is
due to an unfair comparison between RPE-1
p53 null and wild type. In their analyses,
one out of three WT experiments (“UBC”,
using TKOv3) outperforms their single p53
null experiment (done with TKOv2), likely
because (i) it uses more partial replicates,
(ii) the experimental design is more
advanced, using a bottleneck after transduc-
tion to decrease clonal variance (Michlits
et al, 2017; Schmierer et al, 2017), (iii) it
uses better guide-RNA library, and (iv) the
measure used selectively exaggerates its
performance due to overfitting (the guides
for TKOv3 but not TKOv2 were designed
based on the essential gene set they use to
test performance). In contrast, our simpler
analysis using the same number of replicates
for null and wild-type and eliminating poten-
tial for overfitting leads to a result that is
converse to that reported by Brown et al,
and consistent with the model presented in
our original publication.
In addition to not having performed the
same side-by-side experiment using a fair
measure of performance, the design princi-
ples of Brown et al’s screens are materially
different from ours: Our screen was
designed to be robust to clonal variation and
thus allows more sensitive comparison of
assay performance between cell types
(Brown et al panel E). The design by Brown
et al seeks to decrease variation between
cells in order to optimize detection of drop-
outs in all cell types (panel B). Their process
involves separate and careful optimization
of screening performance for each cell line,
making comparisons of screening perfor-
mance between cell types very difficult, if
not impossible. Both design principles are
compromises, and as a consequence, the
screens do not perform equally well in
detecting the converse features. Brown et al
accept that p53 loss is selected for, but argue
that p53 activation does not have major
effects on the performance of CRISPR knock-
out screens in their analyses. We believe
that their failure to detect the p53 effect is in
large part because, to optimize screening
performance, they selected clonal cell lines
that edit efficiently or “screen well”, used
excessive normalization procedures, and
focused on thresholded calls and (overfit)
measures that are too lenient to detect the
underlying differences in performance.
Under such synthetic tests, the true extent of
the variance caused by p53 is normalized
away.
Thus, consistent with a p53 response
hampering screens in normal (untrans-
formed) human cells, MAGeCK analysis of
the raw data reveals that under both our and
Brown et al’s screen designs the perfor-
mance of the p53 null RPE-1 is higher than
that of RPE-1 p53 WT. If one makes the
unsafe assumption that the clonal cell lines
used in Brown et al are fully representative
of parental RPE-1 cells, the observation that
the overall drop-out performance in their
screens is higher is explained most parsimo-
niously by the model we proposed in Haapa-
niemi et al. The key variable is the rate of
Cas9-induced mutagenesis relative to the cell
cycle time. If the mutation rate is much
faster than the cell cycle time, all cells will
be edited within one cell cycle, and p53WT
cells will arrest temporarily during the same
cycle. In this case, the p53-dependent
increase in noise is expected to be at its
minimum and can be missed by investiga-
tors if only highly processed data are
analyzed, or if single cell clones of different
cell lines are compared with each other. If
cutting is slower than the cell cycle time,
there is little difference for a p53 null cell.
For a p53 wild-type cell, however, division
of cells that contain DSBs will be slowed by
p53 (preprint: Geisinger & Stearns, 2019),
whereas cells that happen to edit poorly will
divide. This will still allow efficient detec-
tion of enriched guides, but lead to a
runaway loss of precision in the drop-out
part of the screen. The RPE1-Cas9 cells
Brown et al use seem to heavily overexpress
Cas9 (Zimmermann et al, 2018). This is
expected to lead to very fast kinetics of DNA
cutting, and more persistent binding of Cas9
to its target site after the cut (preprint:
Geisinger & Stearns, 2019). Thus, the very
high Cas9 expression in their cells (Zimmer-
mann et al, 2018) is a plausible explanation
for why both screens detected the positive
selection for loss of p53, but only our
screens clearly distinguished between the
drop-out performance of p53 wild-type and
p53 null cells. We would like to note that it
is our discovery of differences in the
responses of normal and tumor cells to
genome editing that attracted attention to
our work, not the failure to find drop-outs.
We wish to reiterate that selection of cells
that perform well in CRISPR/Cas9 experi-
ments is not without risk. Cas9 cutting intro-
duces a low level of a very genotoxic form
of DNA damage, induces a DNA damage
response, and can lead to severe chromoso-
mal aberrations or large deletions (Kosicki
et al, 2018; Cullot et al, 2019); at least in
primary human cells, the frequency of
occurrence of the large deletions is p53
dependent (Cullot et al, 2019). The DNA
damage response varies as a function of
experimental conditions and cell types and
can induce cell cycle arrest or cell death. As
p53 integrates many cellular stresses, the
magnitude of the response will also depend
on the targeted site (preprint: van den Berg
et al, 2019), the delivery method and other
experimental design parameters. The
measured variables (e.g., fitness, cell cycle)
will interact differentially with DNA damage
and p53. Irrespective of the screen, all hit
genes must thus be formally considered
synthetic with the DNA damage response,
which is a confounding variable in CRISPR
nuclease-based screens. The effect can be
mitigated to some extent in screens targeting
single coding regions as highly specific
guides can be selected; much larger amount
of DNA damage is expected to occur in
screens where less optimal guides are
needed (e.g., those targeting non-coding
regions), or where multiple genes are
targeted simultaneously.
Selection of cells that perform well in
CRISPR screens can help to identify clones
with fast editing kinetics, partially mitigate
the effect of p53, and increase technical
precision. However, it can also easily lead to
selection of cells that are unrepresentative of
the whole population, or inadvertent selec-
tion of cells that have qualitative or quanti-
tative defects in sensing or repairing DNA
damage—potential issues that Brown et al
have not addressed. Selection of clones is
particularly problematic when analyzing
genetic interactions or studying highly aneu-
ploid or genetically unstable cancer cells.
The biologically most relevant results are
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obtained by using populations of cells, opti-
mally in combination with lineage tracing by
UMIs to sample the range of cellular hetero-
geneity (Michlits et al, 2017; Schmierer
et al, 2017). We realize that in some experi-
mental settings, clones are still preferable; in
such case, we would advocate careful genetic
analysis of the clones (e.g., karyotyping), and
systematic labeling of clonal lines in publica-
tions to avoid confusion.
Even though we agree with most of the
advice given by Brown et al on how to
design CRISPR screens to optimize techni-
cal performance in a clone derived from a
given cell line, we disagree with the
broader implication that a particular type
of experiment must always be performed
in a particular way. Design of experiments
must be based on the scientific question
addressed and cannot blindly follow rules
designed for other purposes. It is admit-
tedly counterintuitive that even changes to
experimental design that seem universally
beneficial and completely harmless—such
as optimizing technical performance within
a given framework—can sometimes
hamper scientific discovery. Imposing blan-
ket “quality control standards” and
dismissing experiments that apparently fall
short of them can lead to failure to detect
variables that affect “quality” (Brown et al
panels A–D) and to failure to ask the ques-
tion: Why does experiment A have lower
“quality” than experiment B? Had we dili-
gently followed Brown et al’s advice to
avoid “pitfalls”, made high-performing cell
lines, and emphasized their preferred vari-
able (technical precision) over the variable
that was of more concern to us (variation
within and between cell lines), we would
in all likelihood have failed to perform the
very measurement that ultimately led us to
the actual scientific findings of our original
paper. Finally, although our original work
was focused on the implications of Cas9-
induced p53 activation for precision editing
and for cell-based therapies, we would like
to take this opportunity to also strongly
advise against ignoring p53—the guardian
of the genome—in any study that makes
use of reagents that introduce double-
strand DNA breaks.
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